UBS Group’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

UBS Group’s Portfolio MTACU Stock Details MTACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-606	Closed	-$6.04K	–	11078
2022 Q4	$6.04K	Buy	606 +200	+49%	+$2K	﹤0.01%	9088
2022 Q3	$4K	Hold	406	–	–	﹤0.01%	9454
2022 Q2	$4K	Buy	406 +306	+306%	+$3.01K	﹤0.01%	9207
2022 Q1	$1K	Sell	100 -554	-85%	-$5.51K	﹤0.01%	10036
2021 Q4	$7K	Sell	654 -622	-49%	-$6.37K	﹤0.01%	9199
2021 Q3	$13K	Sell	1,276 -102	-7%	-$1.03K	﹤0.01%	7707
2021 Q2	$14K	Buy	+1,378	New	+$13.9K	﹤0.01%	7733

Other funds holding MTACU

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's MTACU Position: Q1 2023 in Review

UBS Group sold out of MedTech Acquisition Corporation Unit (MTACU) in Q1 2023, closing a stake of 606 shares — an estimated $6.04K sold.

UBS Group first reported a position in MTACU in Q2 2021 and held it in 7 quarters. The position peaked at $14K in Q2 2021. 3 funds tracked by Wall St. Rank hold MTACU as of Q1 2023.

UBS Group reported no remaining MedTech Acquisition Corporation Unit position as of Q1 2023 after selling out during the quarter.
UBS Group sold 606 MedTech Acquisition Corporation Unit shares in Q1 2023, an estimated $6.04K.
UBS Group first reported a position in MedTech Acquisition Corporation Unit in Q2 2021 and held it in 7 quarters.
UBS Group's MedTech Acquisition Corporation Unit position peaked at $14K in Q2 2021.
3 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.